Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Nordisk
Biotech
Gilead culls last MASH program, 2 cancer assets
The dropped oncology assets are a DGKα inhibitor and an MCL1 inhibitor, which join a Novo-partnered MASH program on the scrap heap.
Darren Incorvaia
Aug 8, 2025 11:50am
Altos ascends with new clinical leader—Chutes & Ladders
Aug 8, 2025 8:30am
Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial
Aug 7, 2025 6:30am
Novo Nordisk drops 2 obesity drugs during pipeline clearout
Aug 6, 2025 4:44am
Big Pharma-backed program seeks future beyond animal testing
Aug 1, 2025 5:00pm
Novo Nordisk nominates CEO successor—Chutes & Ladders
Aug 1, 2025 8:30am
